通过在COVID-19管理中使用天然化合物优化抗菌效应
Amin Gasmi1, Asma Gasmi Benahmed2, Maryam Dadar3
1Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.
Current medicinal chemistry
|May 27, 2024
概括
将天然化合物与现有的抗生素和抗病毒药物结合起来,有望对抗耐药细菌和严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2). 这种方法增强了抗微生物潜力,并可能减少副作用,提供了针对COVID-19和抗微生物耐药性的新策略.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 导致全球重大健康问题,导致肺损伤和死亡.
- COVID-19患者容易受到多药性耐药性呼吸道病原体的二次感染,如Pseudomonas aeruginosa和金黄色葡萄球菌.
- 现有的抗生素往往对这些耐药细菌无效,需要新的治疗策略.
研究的目的:
- 审查结合天然化合物与抗生素和抗病毒药物的研究.
- 探索提高抗微生物药物对抗COVID-19和耐药病原体的疗效的策略.
- 为开发新的抗菌剂提供基础.
主要方法:
- 对研究自然化合物和抗微生物药物的协同作用的文献综述.
- 对增强抗微生物活性和潜在减少副作用的数据的分析.
- 综合现有研究以确定有前途的治疗途径.
主要成果:
- 自然化合物可以增加现有的抗生素和抗病毒药物的抗菌活性.
- 组合方法显示出在对抗多药耐药性感染方面的潜力.
- 自然化合物可能提供更安全的替代或辅助疗法,可能减少药物的副作用.
结论:
- 将天然化合物与传统的抗微生物药物结合起来,是对抗COVID-19和抗微生物药物耐药性的有希望的策略.
- 需要进一步的研究来开发基于这些协同作用的组合的新型抗菌剂.
- 这种方法有可能创造更有效,更安全的传染病治疗方法.
更多相关视频
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
01:23Antimicrobial Proteins
979
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
979
01:26COPD: Management Using Bronchodilators and Corticosteroids
195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
01:28Pneumonia IV: Management
322
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
322